{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T23:35:00Z","timestamp":1788305700630,"version":"build-2803163510"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,12,2]],"date-time":"2021-12-02T00:00:00Z","timestamp":1638403200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013365","name":"West China Hospital, Sichuan University","doi-asserted-by":"publisher","award":["2019HXFH038"],"award-info":[{"award-number":["2019HXFH038"]}],"id":[{"id":"10.13039\/501100013365","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Immune-mediated necrotizing myopathy (IMNM) is characterized by markedly elevated creatinine kinase and histologically scattered necrotic muscle fibers and generally associated with autoantibodies against signal recognition particle (SRP) or 3-hydroxy-3-methylglutaryl-coA-reductase (HMGCR). Poor clinical response to conventional therapies and relapses commonly occur in severe cases. Anti-B-cell therapies have been used in refractory\/relapsing cases.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The characteristics of a patient with IMNM associated with anti-SRP antibodies including physical examination, laboratory tests, and disease activity assessment were evaluated. Conventional therapy, belimumab treatment schedule, and follow-up data were recorded. Medical records of IMNM patients treated in our department from September 2014 to June 2021 were reviewed to evaluate the efficacy and safety of anti-B-cell therapy for anti-SRP IMNM. A literature review of patients with anti-SRP IMNM treated with anti-B-cell therapies was performed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We describe a case of a 47-year-old woman with IMNM associated with anti-SRP antibodies who relapsed twice after conventional therapy but showed good response and tolerance to belimumab at 28 weeks follow-up. In this review, three patients from our department were treated with rituximab. Two of the three patients rapidly improved after treatment. Twenty patients and five retrospective studies were included in the literature review. All patients were administered rituximab as an anti-B-cell drug.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Despite a lack of rigorous clinical trials, considerable experience demonstrated that anti-B-cell therapy might be effective for patients with IMNM associated with anti-SRP antibodies. Belimumab in association with steroids might be an encouraging option for refractory\/relapsing cases.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2021.777502","type":"journal-article","created":{"date-parts":[[2021,12,2]],"date-time":"2021-12-02T10:46:16Z","timestamp":1638441976000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":18,"title":["Belimumab for Immune-Mediated Necrotizing Myopathy Associated With Anti-SRP Antibodies: A Case Report and Retrospective Review of Patients Treated With Anti-B-Cell Therapy in a Single Center and Literature"],"prefix":"10.3389","volume":"12","author":[{"given":"Bei-Bei","family":"Cui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-Ru","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-Yue","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geng","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qibing","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,12,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.nmd.2017.09.016","article-title":"Immune-Mediated Necrotizing Myopathies Working Group ENMC International Workshop. 224th ENMC International Workshop: Clinico-Sero-Pathological Classification of Immune-Mediated Necrotizing Myopathies Zandvoort, The Netherlands, 14\u201316 October 2016","volume":"28","author":"Allenbach","year":"2018","journal-title":"Neuromuscul Disord"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00296-021-04904-5","article-title":"Myopathy Associated With Anti-Signal Recognition Particle Autoantibodies With Pulmonary Involvement and Response to RTX","volume":"4","author":"Mazeda","year":"2021","journal-title":"Rheumatol Int"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S270114","article-title":"Immune-Mediated Necrotizing Myopathy Initially Presenting as Erythema Nodosum","volume":"13","author":"Ying","year":"2020","journal-title":"J Inflamm Res"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/practneurol-2018-002168","article-title":"Difficult Case: RTX in Anti-SRP Antibody Myositis in Pregnancy","volume":"19","author":"Mehta","year":"2019","journal-title":"Pract Neurol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.reuma.2017.02.009","article-title":"Rituximab Therapy in Necrotizing Autoimmune Myopathy Associated With Anti-SRP Antibody: A Clinical Case Review","volume":"14","author":"N\u00f3voa Medina","year":"2018","journal-title":"Reumatol Clin (Engl Ed)"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/cen3.12469","article-title":"Case of Immune-Mediated Necrotizing Myopathy Associated With Anti-Signal Recognition Particle Autoantibodies: Dramatic Improvement After Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone Therapy for Intravascular Large B-Cell Lymphoma","volume":"9","author":"Komiya","year":"2018","journal-title":"Clin Exp Neuroimmunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1097\/CND.0000000000000208","article-title":"Case of Anti-Single Recognition Particle-Mediated Necrotizing Myopathy After Influenza Vaccination","volume":"19","author":"Mamarabadi","year":"2018","journal-title":"J Clin Neuromuscul Dis"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20219","article-title":"Rituximab Therapy for Myopathy Associated With Anti-Signal Recognition Particle Autoantibodies: A Case Series","volume":"62","author":"Valiyil","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/bcr-2014-206250","article-title":"Immune-Mediated Necrotising Myopathy Associated With Antibodies to the Signal Recognition Particle Treated With a Combination of Rituximab and Cyclophosphamide","volume":"3","author":"Fernandes das Neves","year":"2015","journal-title":"BMJ Case Rep"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11845-014-1207-z","article-title":"Novel Antibody Associations in Immune-Mediated Necrotising Myopathy Without Inflammation","volume":"185","author":"Curtin","year":"2016","journal-title":"Ir J Med Sci"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep027","article-title":"Poor Response of Anti-SRP-Positive Idiopathic Immune Myositis to B-Cell Depletion","volume":"48","author":"Whelan","year":"2009","journal-title":"Rheumatology (Oxf Engl)"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2006.03.002","article-title":"Marked Efficacy of a Therapeutic Strategy Associating Prednisone and Plasma Exchange Followed by RTX in Two Patients With Refractory Myopathy Associated With Antibodies to the Signal Recognition Particle (SRP)","volume":"16","author":"Arlet","year":"2006","journal-title":"Neuromuscul Disord"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/art.30613","article-title":"A Phase III, Randomized, Placebo-Controlled Study of Belimumab, a Monoclonal Antibody That Inhibits B Lymphocyte Stimulator, in Patients With Systemic Lupus Erythematosus","volume":"63","author":"Furie","year":"2011","journal-title":"Arthritis Rheum"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203991","article-title":"Efficacy and Safety of Belimumab in Primary Sj\u00f6gren\u2019s Syndrome: Results of the BELISS Open-Label Phase II Study","volume":"74","author":"Mariette","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/art.40358","article-title":"Belimumab for the Treatment of Early Diffuse Systemic Sclerosis: Results of a Randomized, Double-Blind, Placebo-Controlled, Pilot Trial","volume":"70","author":"Gordon","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/annrheumdis-2018-213496","article-title":"Anticardiolipin and Anti-Beta 2 Glycoprotein-I Antibodies Disappearance in Patients With Systemic Lupus Erythematosus and Antiphospholipid Syndrome While on Belimumab","volume":"77","author":"Sciascia","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2004.02.006","article-title":"119th ENMC International Workshop: Trial Design in Adult Idiopathic Inflammatory Myopathies, With the Exception of Inclusion Body Myositis, 10-12 October 2003, Naarden, The Netherlands","volume":"14","author":"Hoogendijk","year":"2004","journal-title":"Neuromuscul Disord"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/art.30344","article-title":"Correlation of Anti-Signal Recognition Particle Autoantibody Levels With Creatine Kinase Activity in Patients With Necrotizing Myopathy","volume":"63","author":"Benveniste","year":"2011","journal-title":"Arthritis Rheum"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/acr.22920","article-title":"Longitudinal Course of Disease in a Large Cohort of Myositis Patients With Autoantibodies Recognizing the Signal Recognition Particle","volume":"69","author":"Pinal-Fernandez","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2016.08.013","article-title":"Treatment and Outcomes in Necrotising Autoimmune Myopathy: An Australian Perspective","volume":"26","author":"Ashton","year":"2016","journal-title":"Neuromuscul Disord"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1212\/NXI.0000000000000513","article-title":"Seronegative Patients Form a Distinctive Subgroup of Immune-Mediated Necrotizing Myopathy","volume":"6","author":"Lim","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B22","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1186\/s13023-020-01431-7","article-title":"Factors Associated With Refractory Autoimmune Necrotizing Myopathy With Anti-Signal Recognition Particle Antibodies","volume":"15","author":"Zhao","year":"2020","journal-title":"Orphanet J Rare Dis"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13075-014-0454-8","article-title":"Expression of BAFF Receptors in Muscle Tissue of Myositis Patients With Anti-Jo-1 or Anti-Ro52\/anti-Ro60 Autoantibodies","volume":"16","author":"Kry\u0161t\u016ffkov\u00e1","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"B24","doi-asserted-by":"publisher","first-page":"395","DOI":"10.2217\/bmm.13.124","article-title":"B-Cell Activating Factor as a Serological Biomarker for Polymyositis and Dermatomyositis","volume":"8","author":"Peng","year":"2014","journal-title":"biomark Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2001180","article-title":"Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis","volume":"383","author":"Furie","year":"2020","journal-title":"N Engl J Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13023-015-0277-y","article-title":"Inflammatory Myopathy With Anti-Signal Recognition Particle Antibodies: Case Series of 100 Patients","volume":"13","author":"Suzuki","year":"2015","journal-title":"Orphanet J Rare Dis"},{"key":"B27","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.jneuroim.2013.08.008","article-title":"Complement-Mediated Muscle Cell Lysis: A Possible Mechanism of Myonecrosis in Anti-SRP Associated Necrotizing Myopathy (ASANM)","volume":"15","author":"Rojana-udomsart","year":"2013","journal-title":"J Neuroimmunol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/annrheumdis-2018-213518","article-title":"In Vivo Pathogenicity of IgG From Patients With Anti-SRP or Anti-HMGCR Autoantibodies in Immune-Mediated Necrotising Myopathy","volume":"78","author":"Bergua","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1212\/WNL.0000000000004923","article-title":"Necrosis in Anti-SRP and Anti-HMGCRmyopathies: Role of Autoantibodies and Complement","volume":"90","author":"Allenbach","year":"2018","journal-title":"Neurology"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.777502\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,2]],"date-time":"2021-12-02T10:46:18Z","timestamp":1638441978000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.777502\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,2]]},"references-count":29,"alternative-id":["10.3389\/fimmu.2021.777502"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.777502","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,2]]},"article-number":"777502"}}